

MEMBER GROUPS

ABHI

CANCER Chair: Jane Coppard, Roche Diagnostics Vice Chair: Chengetayi Pswarayi, Terumo

To bring together NHS, cancer research organisations and industry to develop innovative pathways for cancer treatment that utilises health technologies to help deliver the objectives of

the NHS Long Term Plan with particular focus on:

Achievements

> Early and faster diagnosis through the use of sophisticated digital health tools, better diagnostics testing and improved access to screening and diagnostics programmes.

Access to a wider range of effective management options to improve outcomes through personalised treatment regimes. > Integrated modality treatment with genomics, pharma

and devices.

/ one vernento	
Published a case study compendium illustrating how	
member's technologies can support the delivery of cancer	
services during and post-pandemic.	

Provided members with ongoing information regarding the impact of COVID on cancer services and status of non-urgent care.

Priorities

Ensure key stakeholders are aware how HealthTech solutions (diagnostics and interventions) can help tackle waiting lists and support the cancer recovery plan.

To establish a collaborative platform with key stakeholders to support the call for a Cancer innovation fund for HealthTech.

Identify key technology areas to develop innovative processes for rapid market entry aligned to ABHI's Accelerated Transitional Adoption Scheme (ATAS) proposals.



"Cancer is one of the highest profile areas of healthcare and health technology has an important role to play in supporting patients and clinician to access appropriate treatments. Through diagnostic technology we can support the NHS to achieve its Long Term Plan targets, helping to save even more lives by catching more cancers early and starting treatment fast. HealthTech can also provide a wider range of therapeutic opportunities and the group is focused on how we can support clinicians access the best treatment and diagnostic tools."

Jane Coppard, Public Affairs Manager, Roche & Chair, ABHI Cancer



ABHI

CARDIOVASCULAR

Chair: Declan Dunphy, Cook Medical

Heart Valve

Chair: Jane Nixon, Medtronic Vice Chair: Nick Walker. Edwards

Stroke

Chair: Amy Peters, Johnson & Johnson

The Cardiovascular Group at ABHI brings together the various working groups that relate to the cardiovascular (CV) system. The group is intended to bring a high-level view of the impact of CV challenges to the NHS and more widely to the UK population in terms of welfare spending and the impact on the overall economy. It has three key working groups focused on; vascular technologies, the prevention, diagnosis and treatment of stroke and heart valve disease.

Achievements

With ABHI member support, the Vascular Society has run the To work on the implementation of the recommendations first pilot of a device-specific registry for abdominal aortic outlined in the Cardiovascular Health Check Report. aneurysm (AAA) procedures and is now looking to expand the device specific nature of the registry into other clinical areas.

Members coordinated a robust response to the AAA NICE Consultation, delivering broad stakeholder agreement and continued insight sharing.

Developed a Cardiovascular Health Check Report to help the group achieve its mission, vision and purpose.

"Where in your business life can you work hand-in-hand with industry colleagues and medical societies with an open, transparent and collaborative approach for the better good of the patients? The only place I can think of is ABHI Cardiovascular."

Declan Dunphy,

Manager, Commercial Business EMEA Vascular Division, Cook Medical & Chair, ABHI Cardiovascular






Vascular

Chair: Denise Bryceland, Terumo Vice Chair: Robert White, Boston Scientific

Priorities


To coordinate activity across the sub-sector member groups so a collective voice can tackle common challenges.



Chair: Greg Quinn, BD Vice Chair: Samantha Howard, Abbott

The voice of the Diabetes management industry. Working alongside people with diabetes, clinicians, health systems, and support groups/charities to make available the highest quality, sustainable, technology-based solutions to treat and manage diabetes.

Achievements	Priorities
Joint ABHI and Diabetes Technology Network (DTN) position on Insulin Pumps.	Articulate the value of the diabetes technology community, providing people with diabetes with equity of access t o the highest quality, sustainable, technology-based solutions t o treat and manage their condition.
Briefing from All Party Parliamentary Group for Diabetes to the ABHI Diabetes group.	Build and strengthen relationships with identified stakeholders.
Utilised the publication of the GIRF T diabetes report to identify key areas of focus for industry.	Respond as a group to appropriate consultations and policy positions to position the value of the diabetes tech community.



"My experience of the ABHI diabetes group has been very valuable. As a new SME player in the market, it has been great to come together with the other players in the sector to understand our common pain points and goals. The group is well structured and run and I am sure is going to get better and better as we mature."

Alex Evans, Country Manager, ViCentra





DIAGNOSTICS

Vice Chair: Bruce Caldwell, BD

The group brings together a broad range of stakeholders across Government, NHS, academia, research and industry to enable the vision of an early and holistic diagnosis healthcare model. It is the expert industry group, connecting-up different diagnosis sectors within the industry with external specialists and leaders. The group provides knowledge and leadership to progress the early diagnosis model and build high levels of diagnosis capacity and capability in the UK. ABHI Diagnostics also focuses on antimicrobial resistance (AMR). With infections getting harder to treat, tackling AMR requires a holistic approach, from education and awareness, through to the application of diagnostics tools to identify pathogens that inform the appropriate therapies, as well as management of complications such as sepsis.

Achievements	Pi
Partnered with NHS England/Improvement to publish a vision for early diagnosis in the UK with ministerial support.	Es int sta kn
Provided industry leadership to support rollout of NHS Test and Trace.	Pa en eg in t
	Bu

"Diagnostics has been catapulted into the public eye during the last 18 months, showing both the incredible impact we make on healthcare, but also the challenges and legacy of underinvestment that exist. This new-found public presence presents us with an unprecedented opportunity to build the value, investment and infrastructure for diagnostics in the UK. We hope that this group will form a strong singular voice across all areas of our industry to shape national strategy, policy and implementation, to help build a world leading diagnostics sector."

Pierre Hazlewood, Director of Marketing, Roche & Chair, ABHI Diagnostics



Priorities

Establish ABHI Diagnostics as the authoritative, credible interlocutor between the diagnostics industry and stakeholders, providing strategic industry leadership, snowledge and influence.

Partner with stakeholders to provide structured industry engagement and input to the development and rollout of strategies and policies to grow diagnostics capability and capacity n the UK.

Build and grow ABHI's diagnostics community.



DIGITAL HEALTH

Chair: Dr Roberto Liddi, Sensyne Health Vice Chair: Anne Dreyer, Roche Diagnostics & Michael Shenouda, Open Medical

Building on unique opportunities in the NHS, academic institutions and third sector, the Digital Health Group works with national organisations to ensure the UK maximises opportunities for citizen health and economic wealth by investment in data-driven healthcare and creates a strong infrastructure and commercial environment to support development of the best HealthTech solutions.

Achievements	Priorities
Published White Paper on Digital Health Regulations to take an industry leadership position.	 Market Access: Highlight issues within the financial system that hinder adoption of digital health technologies and make formal recommendations, based on the ABHI White paper, for changes and additions to reimbursement mechanisms covering all aspects of digital health technologies. <u>ABHI Paper: Health Digital Reimbursement</u>
Established a Task and Finish group under the Accelerated Access Collaborative to address specific Digital Health market access issues.	2. Data: Engage with key stakeholders to ensure industry input, as outlined in the ABHI White Paper, is incorporated in the development of data strategies, policies and processes, facilitating streamlined industry access to data industry. <u>ABHI Paper: Health Data Access & Use</u>
Supported MPs to establish and provide ongoing secretariat support for an All Party Parliamentary group on Digital Health.	3. Regulation: Work with relevant organisations to get industry recommendations on regulation across product and data built into legislation and working processes. <u>ABHI Paper: Digital Health Regulation</u>
Provided industry input into a wide range of policy initiatives including: NICE Digital Assessment programme & Multi Agency Advice Service, NHSX, Digital Technology Assessment Criteria, Scottish Life Science Group, HDR UK Innovation Portal and the Office for Life Sciences Health Data Policy.	4. AI & Ethics: Work with academia and third parties to establish practical tools and guidelines to support industry development and deployment of AI technologies.
	5. Remote Management: Develop a series of case studies to highlight industry capabilities and system benefits to be gained by implementation of remote management systems.
	Adoption Based on above activities, develop and publish a "State of the Nation' report that highlights the changes required for the UK health and

Nation' report that highlights the changes required for the UK health and care system to rapidly and systematically adopt new technologies and the benefits to be gained for both NHS and UK economy.

"Since the groups inception I have been proud to work with members to develop an active programme of work and engagement with external stakeholders. We have clearly laid out positions on key topics which are disseminated through the broader platforms available via the ABHI interactions with ministers, senior officials and NHS leaders. Digital HealthTech is one of the fastest growing sectors in the medical device world, working at the intersection between regulation, software technology, ethics and information governance, and it is imperative for the industry that all of those angles are covered adequately."



HR LEADERS NETWORK

Chair: Jonathan Coles, Philips Vice Chair: Emma Carter, Bayer Plc

The HR Leaders Network identifies and responds to factors that impact talent development across the HealthTech sector. It provides an opportunity for members to work together on industry-specific skills initiatives, share best practice, keep updated on employment legislation, and broaden the network of partners and stakeholders with whom to collaborate on mutual priorities. The group is also exploring how it can advance equality, diversity and inclusion in HealthTech.

Achievements	Ρ
Provided guidance and support on HR and workforce related issues to manage the organisational impact of the COVID-19 pandemic, including: • Key worker status • Furlough scheme • Flexible and homeworking • Return to the workplace • COVID testing and vaccination	Co
Assisted organisations to get ready for 1st January 2021 new immigration system.	De ID fle
Provided training and education on implementation of IR35.	Sł ar
	Co ar

"ABHI's HR Leaders Network has grown to become the premier industry specific community for HR professionals. It is a great opportunity to engage with peers in lead HR roles across the HealthTech industry, exchange ideas, share best practice and collaborate on industry challenges, for example on industry skills shortages and managing the impact of COVID on staff and the organisation."

Jonathan Coles.

Head of HR, UK & Ireland, Philips, & Chair, ABHI HR Leaders Network



Priorities

Continue to provide industry leadership on all relevant andemic related workforce and organisational issues.

Develop best practice to assist businesses adapt to post-COV-D-19 organisational implications, including: future workplace, lexible working, benefits, use of technology, skills in a digital vorld and culture.

Share and amplify industry best practice to progress diversity and inclusion in the workforce.

Continued review of the use of apprenticeships in the industry and relevant standards available.



INTERNATIONAL

Chair: TBC Vice Chair: TBC


The International group provides an interface with government for input on trade and investment. The group seeks to identify opportunities for members and works on strategy to best to unlock them. This also includes the development of ABHI's international activity programme, designed to enable UK HealthTech business to expand in global markets.

Priorities

Input into the UK's development of Free Trade Agreements.

Inform the work of the HealthTech International Working Party, which is a sub-group of the Health Technology Partnership, and is focused on co-ordination of international trade activity.

Work with the Department for International Trade and input into sector specific elements of the Department's Export Strategy.







LEGAL ISSUES

Chair: Linda Sneddon, WL Gore Vice Chair: Tosin Umukoro, Stryker

The Legal Issues Group augments the work of other ABHI groups by providing advice and support on legal issues, especially in the UK market and regulatory areas. The group has recently incorporated the Credentialing and Access Group, therefore adding any legal implications to the UK's credentialing network to the discussion.

Achievements

The group has held several external presentations on topics such as Class Actions and Lloyd v Google, and greatly benefits from the general participation of external law firm colleagues.

The Chair of the Code of Ethical Business Practice complaints committee has been made a member of the group, in order to inform the members of infringements to the Code. To consider the pending five-year review of the ABHI Code of Ethical Business Practice in light of potential Medech Europe updates and the challenges presented by social and corporate responsibility requirements.

The Chair and Vice Chair have been instrumental in the drafting of the white paper, related to 'Placed Equipment'.

"The Committee is aiming to provide practical answers to the ongoing challenges. Since the onset of the pandemic there has been significant engagement within the group that aims to provide clarity to all members as a whole."

Linda Sneddon,

Compliance MPD EMEA, Gore & Chair, ABHI Legal Issues



Priorities

To monitor any legal developments presented by the developing UK regulatory requirements, that may affect the HealthTech sector, including those related to diagnostics and digital products.

To develop a strategy for education and encouragement for the regulatory group, thereby fostering an environment of participation by members.



MUSCULOSKELETAL

Orthonaedics

Achievements

of COVID-19.

Steering group.

Chair: Andrew Dalton, Johnson & Johnson Vice Chair: Gary Lancaster, Smith & Nephew

ABHI Musculoskeletal brings together orthopaedics encompassing joints, and spine. Together with stakeholders, including clinicians and patient support groups, we work to shape and improve the future of musculoskeletal care.

Good relationship established with the executive of the British

Orthopaedic Association and various patient organisations.

orthopaedics project has helped in this area of "shaping the

A strong industry voice established when working with our

stakeholders, including United Kingdom Spine Societies

Board/BritSpine, National Joint Registry/Northgate and

Orthopaedic Data Evaluation Panel /Beyond Compliance

environment". The group was reformed to focus on the effect

COVID-19 has presented some challenges, but the

Priorities

services.

compliant method.

stakeholders and patient groups.

Chair: Kate Windard, Nuvasive Vice Chair: Anthony Avery, Johnson & Johnson

To raise the profile and address the implication of arbitrary

restrictions placed on patients needing musculosk eletal

To ensure the appropriate environment for the spinal and

orthopaedics industries to work with the NHS in a safe and

To strengthen the industry voice in our relationships with our





OPHTHALMOLOGY

Chair: Sved Rashid, Johnson & Johnson Vision Vice Chair: Oscar Ayling, Bausch & Lomb UK Ltd

Ophthalmology is facing significant capacity challenges br ought about by the COVID-19 pandemic and ophthalmologists need to plan restoration of cataract surgery, whilst dealing with the challenges of COVID-19 transmission prevention. The ABHI Ophthalmology Group is designed to support the sector.

Achievements	Pr
Convened meeting with the the Royal College of Ophthalmologists and industry.	Ong opł
Industry's objectives on educational and clinical training high- lighted and clinical requirement requested.	Ide for
Individual manufacturers educational offering presented to the Royal College of Ophthalmologists bilaterally.	Eng opł

"Engagement with the group has enabled collaboration to tackle the issues of the day as an industry, rather than just being a lone voice. It has provided education and insight from specialists who understand processes and systems better than me. Engagement with key stakeholders has been richer and quicker as a group than as an individual."

Jeff Stonage, Health Economics and Reimbursement Director, Zimmer Biomet "This is a unique opportunity moving out of the pandemic with a world class vaccination programme, that the Ophthalmology group can effectively engage external key stakeholders to look at ways to collectively manage the challenge of the backlog of elective surgery. This will build trust to have a seamless partnership with the working group and create value for our external stakeholders."

Syed Rashid,

Director of Market Access & Sales Training, Johnson & Johnson Vision & Chair, Ophthalmology Group





riorities

ngoing engagement with the clinical community around ohthalmology service provision.

entify the Royal College of Ophthalmologists requirements support on the restart of ophthalmology.

ngagement with GIRFT regarding the GIRFT ohthalmology Report.



PATIENT SAFETY

Chair: Ian Duncalf, B. Braun Medical Ltd

The group works to establish the HealthTech industry as a trusted partner for improving patient safety by reducing "never events" and providing key inputs to stakeholders implementing the Patient Safety Strategy. The group works closely with the infection prevention community to ensure that the potential of technology is maximised.

Achievements	Priorities
Identified "never events" to address as an industry group.	Raising the profile of the current and future impact of HealthTech on key UK patient safety issues.
Developed patient safety paper focussed on key areas of concern in patient safety.	To foster collaborations between industry and relevant stakeholders.
Industry engaging with Key Stakeholders in the patient safety arena.	To prioritise areas of the Patient Safety Strategy where industry can offer most traction.





PUBLIC AFFAIRS Chair: Nigel Talboys, Terumo

Vice Chairs: Kieran Murphy, ReCor Medical UK & Alan Sumner, Roche Diagnostics

The Public Affairs group is ABHI's main forum for developing and communicating its public affairs strategy. It aims to raise the profile of the benefits and impacts of HealthTech across Parliament and Government, while providing members with the latest insights on legislative change.

	Achievements	Priorit
_	ABHI continued to increase HealthTech representation and input across formal government engagement platforms culminating in a Life Sciences Vision that acknowledges the crucial role of HealthTech.	To ensu of the H (Life Sci Opportu the Inno
_	Securing multiple references in the Life Sciences vision related to ABHI's Chief Innovation Officer campaign, including having innovation and research as a core expectation across the NHS, alongside commitment to building metrics that can be used to monitor improvements.	Work to Science is both r



"The Public Affairs group gives me a single point of contact to keep updated on the legislative developments in the UK, during a time when there are many changes through the divergence in UK legislation from that of the EU."

Nigel Talboys,

Director, Global Government Affairs and Public Policy, Terumo & Chair, ABHI Public Affairs



ities

sure strong impact follows the increased representation HealthTech sector in all formal government engagements ciences Council, Health Technology Partnership, Global tunities Board, Life Sciences Implementation Board and novation Research and Data Group).

to support the commitments within the Life ces Vision that ensures the delivery of innovation resourced and accountable across the NHS.

To inform ABHI's position and activity on key issues in Parliament, particularly where there is a relevant legislative programme.

REGULATORY Medical Device Regulatory

Chair: Lynn Heaver, Johnson & Johnson Medical Vice Chair: Cait Gatt, Boston Scientific IVD Regulatory Chair: TBC Vice Chair: TBC

The Medical Device and IVD Regulatory Groups are ABHI's forums for developing and communicating policy on wider regulatory, environment and standards issues including those covered by UK CA marking, EU MDR and EU IVDR.

The groups work collaboratively with other ABHI member groups to ensure new UK and EU regulations provide safe and timely access to medical devices, IVDs and digital health products, whilst maintaining the balance between risk and benefits for patients.

The groups also bring together a sub group on the decontamination of HealthTech products, that will develop a programme of work supporting decontamination of medical devices and IVDs.

"Being part of the regulatory group is empowering. To be able to have like-minded discussions with peers across many companies only expands your own knowledge. And in our current environment of the MHRA consultation on the future of medical devices, now is the time we can all create change and innovation, to develop along with MHRA the best regulatory system to ensure access to devices for our patients in the UK. As George E. Woodberry said 'Defeat is not the worst of failures. Not to have tried is the true failure'."

Lynn Heaver,

Regulatory Affairs Lead UK/Ireland, Johnson & Johnson Medical & Chair, ABHI Medical Device Regulatory

_	=	
$\overline{}$)

Achievements

Medical Device Regulatory

- Significant and comprehensive input into the UK CA Marking sub-group to influence future UK regulatory framework, including detailed response the MHRA consultation.
- Ensured external presentations into all group meetings on a number of wide-ranging topics, including standards and MHRA process and procedures.
- Included a number of international regulatory presentations in the group discussions, including from Swiss Medtech and MedTech Europe.

IVD Regulatory

- Significant and comprehensive input into the UK CA Marking sub-group to influence future UK regulatory framework, including detailed response the MHRA consultation.
- Led the industry voice on the Coronavirus Test Devices Approvals (CTDA) process.
- Worked closely with MedTech Europe to ensure an extended transition period for IVDR.


Priorities

Medical Device Regulatory

- To work with members of the IVD and digital interest groups to develop a regulatory oversight group, that will ensure messaging is consistent with wider ABHI policy.
- Ensure that ABHI and its members are recognised as the senior partner in MHRA's efforts to progress CA Marking, particularly with respect to timely inputs into the respective consultations.
- To develop a strategy for education and encouragement for the group, thereby fostering an environment of participation by members.

IVD Regulatory

- > Build a strong IVD regulatory group to establish authoritative leadership in the UK.
- Drive the UK industry response to the emerging UK regulatory framework.
- Influence and assess the impact of new IVD regulations and guidelines in the EU and internationally.



BZbWZg<gdjeh



RESPIRATORY & ANAESTHETICS

Chair: Gus Sagoo, ResMed **Vice Chair:** Nicki Dill, Barema

The Respiratory & Anaesthetics Group works to support the development of innovative pathways in respiratory care and progress the use of technology to improve outcomes in anaesthetics and critical care. We will collaborate with stakeholders to help deliver the objectives of the NHS Long Term Plan with particular focus on:

- > Policy formation: payment mechanisms, pathway development, clinical guidelines and standards.
- > Procurement, both capital and consumables.
- The role of health technology in prevention, diagnosis and treatment.

Priorities

Sustainability.

Work with ABHI Sustainability group to provide input and activity related to specific anaesthesiology issues.

Payment Research.

Innovation and priorities for service transformation to tackle Long COVID.

Lung Health.

Engage with key stakeholders to ensure industry input is incorporated in the development of integrated respiratory care, rehabilitation and care at a local level.

Engagement.

Establish systematic engagement with the NHS across all nations, royal colleges and professional bodies, and relevant patient organisations. ABH

ROBOTIC ASSISTED SURGERY

Vice Chair: Daniel Jones, Stryker

This group brings together HealthTech companies, the clinical community and other relevant organisations who have a strong interest in furthering the development of surgical robotic systems and their use in surgery. It aims to be the expert ABHI group, helping inform external audiences on the

Achievements	Pric
Successful group launch with commitment from key opinion leaders to partner with the group and progress robotic-assisted surgery in the UK.	Build shap grou conti
	Crea and r assis
	Raise assis publi

"There are significant benefits to be had in using robotic assisted surgery methods, with less time for patients spent in hospital and quicker recovery times, which in turn supports a more efficient healthcare system. Of course, adoption of such technologies requires training, long-term investment and an appreciation of the value they bring. This is where the ABHI Group comes in, bringing together companies, the clinical community and all those involved in shaping the future of surgery, so that collectively, we can work together to improve outcomes for patients."

Nick Magree,

General Manager Europe - Robotics, Stryker UK & Chair, ABHI Robotic Assisted Surgery



development of surgical robotic systems and their application in surgery. The group will proactively engage a varied network who will shape the future adoption and growth of robotic assisted surgery.

Priorities

Build relationships with organisations actively involved in shaping the future of robotic assisted surgery, ensuring the group is recognised as a trusted partner that engages and contributes to the development of new policies.

Create materials that set out, in plain English, key information and messages relating to surgical robotic systems and robotic assisted surgery in the UK.

Raise the profile of this industry sector, and robotic assisted surgery in general, through events and other public engagements.

ABH



SCOTLAND

Chair: Mark Cook, Medtronic **Vice Chair:** Giles Hamilton, ODx Innovations & Jonathan Williamson, Emblation

The group works with a broad range of stakeholders to raise the profile of the sector in Scotland, identify barriers to patients accessing appropriate technologies and provide tangible solutions. It also works to demonstrate the value of the breadth of solutions available to domestic and global health systems.



Data:

Working to create a shared Health Data Space to enable a national, integrated approach to data that supports technological, clinical and system innovations, creating health and economic benefits for Scottish citiz ens and businesses.

Innovation landscape:

Working to encourage streamlining and creating stronger mechanisms for measuring adoption of technologies with positive guidance. In Scotland the adoption and spread of innovation remains somewhat disjointed between the work under taken by the Scottish Health Technologies Group and the Health Boards.

Internationalisation:

Working to showcase and raise the profile of Scottish excellence in healthcare with the global HealthTech community, while continuing to build a growing domestic industry, both through export and inward investment.

"Scotland is a complex market in its own right and will differ from NHS England on principle alone and is structurally unique. By bringing an industry group to the Scottish table, as a partner in healthcare, both Scotland and the wider life sciences community will benefit"

Mark Cook, Director, Government Affairs, Medtronic UKI & Chair, ABHI Scotland



SURGICAL INSTRUMENTS Chair: Daniel Coole, Surgical Holdings

Vice Chair: Darby Booth, Warwick SASCo

The ABHI Surgical Instruments group represents manufacturers of surgical instruments and associated equipment. It is designed to raise awareness of the value provided by surgical products and the importance of continual quality improvement, with a focus on

Production of the Surgical Instrument Strategy document which identified three key recommendations.	To pro
Convened a virtual round table with key stakeholders to discuss the Surgical Instrument Strategy document recommendations.	To sur and
Working group formed to develop an online training course.	То

"Warwick SASCo has been members of the Surgical group for 10 years. The platform allows for vital two-way communications of industry knowledge. That ABHI has its 'finger on the pulse' of UK and international health sectors has a direct effect on my company's positioning and actions to remain a leading supplier of medical devices and healthcare products. Participation in the Surgical group allows for co-operation and engagement with other key UK companies involved in surgery, instrument management and decontamination. I recommend you join."

Darby Booth, Managing Director, Warwick SASCo Ltd & Vice Chair, ABHI Surgical



patient safety and clinical performance. In working to develop and highlight best practice, the group provides a forum for its members to share insights and overcome the challenges impacting the sector.

Priorities

o ensure this industry sector is seen as safe, accountable, professional and equitable.

To raise awareness of the value provided by surgical equipment, with a focus on patient safety and clinical performance.

To be inclusive of all relevant industry manufacturers e.g. single use and reusable instruments.

"A Group of dedicated reusable and disposable companies working together to provide the NHS and private sector with quality products, along with education and support. Together, striving to help hospitals and staff with their everyday work as a reliable source of information."

Andrew Davidson, Advisor, DTR Medical

SUSTAINABILITY

Chair: Michelle Sullivan, Boston Scientific

ABHI Sustainability brings together industry expertise across HealthTech to a develop and communicate ABHI's Environmental Sustainability strategy. It aims to raise the profile of how the HealthTech industry is contributing towards the net zero targets while ensuring regulatory legislation and procurement is taking a holistic approach to HealthTech within the sustainability agenda.

Achievements

Priorities

Establishing a series of four areas of industry alignment around the impact of Net Zero in NHS Procurement.

Established ABHI Sustainability as a forum for feedback to NHS England & NHS Improvement, for the proposed supplier asks and Evergreen Supplier Framework. Establish a series of industry challenges to demonstrate HealthTech's commitment to supporting NHS Net Zero.

Develop ABHI Sustainability into the industry voice that stakeholders recognise and value engagement with.

"Sustainability is an area of increasing significance to all our lives. In 2020, the NHS set out a bold ambition to become the world's first carbon net zero national health system by 2045. As a key part of that global supply chain, and its subsequent footprint, the HealthTech industry has an important role to play. The sustainability group will work to both promote sustainability within the HealthTech industry and for a holistic approach to be taken within regulation and NHS Procurement.'

Annemarie Van Neck,

Senior Vice President UK & Ireland, Coloplast & ABHI Vice Chair





WOUND CARE

Chair: Trevor Andrews, L&R Vice Chair: Charlotte Butterfield, Convatec

To represent Wound Care manufacturers to external stakeholders, to raise the profile of tissue viability as a critical service and the role that technology and industry performs in delivering patient outcomes, experience and system efficiency.

Achievements	Prior
Utilised infographics to highlight the burden of wound care to a wide range of stakeholders including National Wound Care Strategy, NHS Supply Chain, clinical communities and NHS England.	To guio evaluat lowest
Initiated discussions with NHS England and NHS Supply chain around whole-life system cost for wound care products.	To pror manag awarer
	To sup decisio
	Drive for includir and pro

"The ABHI Wound Care group is very useful for our company to be a part of. Membership of ABHI overall, enables us to connect into the UK healthcare system at a high level, with the Group helping to make sense of the current healthcare environment."

Trevor Andrew,

Commercial Strategy Manager, L&R Medical & Wound Care Group Vice Chair



rities

ide clinical and procurement decision makers to consider and ate whole-life system cost for wound care products versus t acquisition cost.

promote value of appropriate evidence in wound gement; working with clinical stakeholders to create eness of the sector challenges.

apport the inclusion of patient views and outcomes in on making.

Drive for greater alignment from key government stakeholders, including National Wound Care Strategy, NHS Supply Chain and procurement organisations.

ABHI

VALUE & ACCESS

Chair: Graeme Cameron, Pennine Healthcare Vice Chairs: Matthew Bramley, Cook Medical & Michelle Sullivan, Boston Scientific

Market Access:

Chair: Kieran Murphy, ReCor Medical UK Vice Chairs: Mark Chapman, Medtronic & Julian Dunnett, Intuitive Surgical Ltd & David Dawson, Becton Dickinson UK Ltd

The Value and Access group is the combined Commercial Policy group and Market Access Policy group. It brings together our work on the adoption and spread of innovation and the commercial uptake by the NHS, while allowing the specific needs of market access and procurement to be addressed. The objective of the group is to ensure that the NHS takes a value-based approach to the assessment, adoption and procurement of health technologies across the system.

"During these most challenging of times the support of the ABHI has never been more critical. The Value & Access group is a group of like-minded suppliers to the NHS who are passionate about ensuring that the correct quality and access to medical technology is provided for the benefit of all patients. Despite the coronavirus crisis we have never stopped in trying to push forward with this vision driven by constant dialogue with Supply Chain Coordination Limited to deliver operational equity, while delivering on the ultimate goal of ensuring that value-based procurement and healthcare become the bedrock of NHS procurement."

Graeme Cameron, CEO, Pennine Healthcare & Chair, ABHI Commercial "Covering the way health technologies are assessed, commissioned and hospitals reimbursed, market access is critical to commercial success of ABHI members. The Market Access group works to ensure the NHS enables timely access to benefit patients and the wider health system. In an everchanging landscape, it is critical that the health technology industry works effectively with Government and the NHS to realise these benefits and remove barriers which work against achieving the best patient outcomes within an efficient health system across the UK."

Kieran Murphy,

Senior Director, Market Access, ReCor Medical UK & Chair, ABHI Market Access

Achievements

Commercial

- > Delivered paper to Ministers on procurement landscape and 10 recommendations for the future requirements of NHS procurement.
- > Created key commercial messages and led engagement with NHS Supply Chain on critical issues.
- > Collated examples of innovations used to support the NHS > Deliver the developed key messages in any engagement with during the COVID-19 crisis, which were shared with NICE, Supply Chain Coordination Limited and Category Towers. the Accelerated Access Collaborative and NHS Wales Value > Through quarterly members survey and quarterly meetings Based Procurement.

Market Access

- > Delivered ABHI Paper to NICE on critical aspects for inclusion in the Methods and Process Review.
- > Group members provided input to the NICE Methods and Process Review Task & Finish groups ensuring sector voice taken into account. The Case for Change consultation included points provided by members.
- > Provided critical feedback on the MedTech Funding Mandate Policy to instigate change in the requirement for in-year savings.

22

Priorities

Strategic Commercial - value not price

- > End era of NHS policy of zero inflation, as it is no longer sustainable after 10 years, using developed costs to serve data.
- > Engage with the royal colleges, Getting it Right Frist Time and NHS England clinical teams to increase expertise and knowledge of value-based healthcare.
- > Embed value-based procurement (VBP) and support training of NHS procurement and Category Towers of VBP, including through collaboration with the NHS Supply Chain VBP work.

SCCL Operational Engagement


- with NHS Supply Chain, create a solution orientated approach to partnership working with NHS Supply Chain and Category Towers.
- > Building on the 10 recommendations for change collated from suppliers, drive improved processes for planning and
- responding to future pandemics.

NICE

- > Hold NICE to account in confirming and delivering on timelines to make incremental changes to the methods & process and topic selection for Health Tech as set out by ABHI in 2021 (managed access and commercial arrangements, topic selection routing and cost saving requirements for HealthTech).
- > Gain agreement from NICE for an annual informal review of methods and process and topic selection for HealthTech to ensure progress and fit for purpose.

Adoption of Innovation

- > Support the AAC, NICE and NIHR to turn the Accelerated Transitional Access Scheme (ATAS) into a reality, once 2022-2023 spending review allocations confirmed.
- > Accelerated Access Collaborative Priority Area 3 review of programmes to support innovation.
- > Ensure that the DHSC MedTech Directorate strategy approach to innovative HealthTech aligns with the Life Sciences vision, and does not adversely impact patient access to innovative technologies through cost containment.
- > Understand the mechanism for devolving operational specialised commissioning to ICS and ensure no reversal to 'postcode lottery' for access to services specialised commissioning are accountable for in the process.



January 2022



Association of British HealthTech Industries Suite 2, 4th Floor, 1 Duchess St, London, W1W 6AN

A company limited by guarantee. Registered in England no. 1469941. Registered office as above. +44 (0)20 7960 4360 enquiries@abhi.org.uk www.abhi.org.uk **y** @UK_ABHI